EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor

Isabelle Sermet-Gaudelus, Pauline Sadrieh, Anne Sophie Bonnel, Raphael Enaud, Nathalie Wizla, Jeanne Languepin, Ambre Nangui, Audrey Deelawon, Johanna Rave, Samira Dabelow, Anton Barucha, Carlos Zagoya iD und 2 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70244 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Isabelle Sermet-Gaudelus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université de Paris, Paris, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Multiorgan abdominal involvement is a hallmark of Cystic fibrosis (CF). The CFAbd‐Score © is the first CF‐specific gastrointestinal patient reported outcome‐measure (PROM) developed following FDA‐guidelines. The PROM has proved to sensitively differentiate people with CF (pwCF) from healthy controls (HC). Furthermore, higher Scores in pwCF are associated with pancreatic insufficiency and history of surgery. Recently, in two large cohorts of pwCF, the PROM revealed significant and clinically meaningful improvements in abdominal symptoms (AS) in pwCF treated with Elexacaftor‐Tezacaftor‐Ivacaftor (ETI). In the present publication, we aim to validate the translated, linguistically and cross‐culturally adapted French version of the CFAbd‐Score © .

Methods

Validation was performed following two forward translations and a review process by a German professional medical translator. The reviewed consensus version was psychometrically evaluated for validity and reliability in French‐speaking pwCF and HC cohorts, as well as in pwCF with and without ETI.

Results

A total of 64 French‐speaking pwCF (mean age: 12.5 years) and 58 HC were included. Median CFAbd‐Score © in pwCF without ETI was significantly higher than in HC (18.2 vs . 8.7 points/ p < 0.01), while Scores from ETI‐treated pwCF were almost as low as the HC‐range in many domains. Scores from ETI‐treated and nontreated pwCF differed significantly (8.4 vs . 18.2 points/ p < 0.01).

Conclusion

The French version of the CFAbd‐Score has proved to be reliable and sensitive to capture AS in French‐speaking pwCF and to distinguish pwCF from HC. Furthermore, consistent with previous findings, the PROM sensitively detects ETI‐related differences in AS of pwCF with and without ETI therapy, and thus can be used in research and clinical routine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesPatient Reported Outcome MeasuresGastrointestinal DiseasesIndolesPyrazolesPyridinesHumansMaleFemaleChildDrug CombinationsReproducibility of ResultsAdolescentFrancePsychometricsChloride Channel AgonistsAdultPyrrolidinesQuinolines

Stichwörter der Autor:innen

CFTRabdominal symptomsmodulator therapypatient‐reported outcome measurescoring

Substanzen

AminophenolsBenzodioxolesQuinolonesDrug CombinationsIndolesPyrazolesPyridineselexacaftor, ivacaftor, tezacaftor drug combinationChloride Channel Agonistselexacaftor

Autor:innen und Institutionen

  • Université de Paris, Paris, France.
  • INSERM U1151, Institut Necker Enfants Malades, Paris, France.
  • Centre de Référence Maladie Rare-Mucoviscidose, Hôpital Necker Enfants Malades, Paris, France.
  • European Reference Network-Lung, Frankfurt, Germany.
  • Cystic Fibrosis Centre, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
  • Faculty of Health Sciences Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany.

ORCID-Profile: Carlos Zagoya, Jochen Georg Mainz

Förderung

  • Vertex Therapeutics

Zitieren

APA

Sermet-Gaudelus, I., Sadrieh, P., Bonnel, A. S., Enaud, R., Wizla, N., Languepin, J., Nangui, A., Deelawon, A., Rave, J., Dabelow, S., Barucha, A., Zagoya, C., Duckstein, F., & Mainz, J. G. (2026). The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70244

Vancouver

Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, et al. The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70244

BibTeX
@article{SermetGaudelus2026,
  author = {Sermet-Gaudelus, Isabelle and Sadrieh, Pauline and Bonnel, Anne Sophie and Enaud, Raphael and Wizla, Nathalie and Languepin, Jeanne and Nangui, Ambre and Deelawon, Audrey and Rave, Johanna and Dabelow, Samira and Barucha, Anton and Zagoya, Carlos and Duckstein, Franziska and Mainz, Jochen Georg},
  title = {The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70244}
}
Kostenlos starten →